-
Je něco špatně v tomto záznamu ?
Uncovering mechanisms of thiazolidinediones on osteogenesis and adipogenesis using spatial fluxomics
K. Brejchova, M. Rahm, A. Benova, V. Domanska, P. Reyes-Gutierez, M. Dzubanova, R. Trubacova, M. Vondrackova, T. Cajka, M. Tencerova, M. Vrabel, O. Kuda
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- adipogeneze * účinky léků MeSH
- buněčná diferenciace účinky léků MeSH
- hypoglykemika farmakologie MeSH
- kultivované buňky MeSH
- lidé MeSH
- metabolomika MeSH
- mezenchymální kmenové buňky * účinky léků metabolismus MeSH
- osteogeneze * účinky léků MeSH
- pioglitazon farmakologie MeSH
- rosiglitazon farmakologie MeSH
- thiazolidindiony * farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: Insulin-sensitizing drugs, despite their broad use against type 2 diabetes, can adversely affect bone health, and the mechanisms underlying these side effects remain largely unclear. Here, we investigated the different metabolic effects of a series of thiazolidinediones, including rosiglitazone, pioglitazone, and the second-generation compound MSDC-0602K, on human mesenchymal stem cells (MSCs). METHODS: We developed 13C subcellular metabolomic tracer analysis measuring separate mitochondrial and cytosolic metabolite pools, lipidomic network-based isotopologue models, and bioorthogonal click chemistry, to demonstrate that MSDC-0602K differentially affected bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs). In BM-MSCs, MSDC-0602K promoted osteoblastic differentiation and suppressed adipogenesis. This effect was clearly distinct from that of the earlier drugs and that on AT-MSCs. RESULTS: Fluxomic data reveal unexpected differences between this drug's effect on MSCs and provide mechanistic insight into the pharmacologic inhibition of mitochondrial pyruvate carrier 1 (MPC). Our study demonstrates that MSDC-0602K retains the capacity to inhibit MPC, akin to rosiglitazone but unlike pioglitazone, enabling the utilization of alternative metabolic pathways. Notably, MSDC-0602K exhibits a limited lipogenic potential compared to both rosiglitazone and pioglitazone, each of which employs a distinct lipogenic strategy. CONCLUSIONS: These findings indicate that the new-generation drugs do not compromise bone structure, offering a safer alternative for treating insulin resistance. Moreover, these results highlight the ability of cell compartment-specific metabolite labeling by click reactions and tracer metabolomics analysis of complex lipids to discover molecular mechanisms within the intersection of carbohydrate and lipid metabolism.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009296
- 003
- CZ-PrNML
- 005
- 20250429135054.0
- 007
- ta
- 008
- 250415e20250211xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.metabol.2025.156157 $2 doi
- 035 __
- $a (PubMed)39947516
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Brejchova, Kristyna $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 245 10
- $a Uncovering mechanisms of thiazolidinediones on osteogenesis and adipogenesis using spatial fluxomics / $c K. Brejchova, M. Rahm, A. Benova, V. Domanska, P. Reyes-Gutierez, M. Dzubanova, R. Trubacova, M. Vondrackova, T. Cajka, M. Tencerova, M. Vrabel, O. Kuda
- 520 9_
- $a OBJECTIVE: Insulin-sensitizing drugs, despite their broad use against type 2 diabetes, can adversely affect bone health, and the mechanisms underlying these side effects remain largely unclear. Here, we investigated the different metabolic effects of a series of thiazolidinediones, including rosiglitazone, pioglitazone, and the second-generation compound MSDC-0602K, on human mesenchymal stem cells (MSCs). METHODS: We developed 13C subcellular metabolomic tracer analysis measuring separate mitochondrial and cytosolic metabolite pools, lipidomic network-based isotopologue models, and bioorthogonal click chemistry, to demonstrate that MSDC-0602K differentially affected bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived MSCs (AT-MSCs). In BM-MSCs, MSDC-0602K promoted osteoblastic differentiation and suppressed adipogenesis. This effect was clearly distinct from that of the earlier drugs and that on AT-MSCs. RESULTS: Fluxomic data reveal unexpected differences between this drug's effect on MSCs and provide mechanistic insight into the pharmacologic inhibition of mitochondrial pyruvate carrier 1 (MPC). Our study demonstrates that MSDC-0602K retains the capacity to inhibit MPC, akin to rosiglitazone but unlike pioglitazone, enabling the utilization of alternative metabolic pathways. Notably, MSDC-0602K exhibits a limited lipogenic potential compared to both rosiglitazone and pioglitazone, each of which employs a distinct lipogenic strategy. CONCLUSIONS: These findings indicate that the new-generation drugs do not compromise bone structure, offering a safer alternative for treating insulin resistance. Moreover, these results highlight the ability of cell compartment-specific metabolite labeling by click reactions and tracer metabolomics analysis of complex lipids to discover molecular mechanisms within the intersection of carbohydrate and lipid metabolism.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a thiazolidindiony $x farmakologie $7 D045162
- 650 12
- $a adipogeneze $x účinky léků $7 D050156
- 650 12
- $a osteogeneze $x účinky léků $7 D010012
- 650 12
- $a mezenchymální kmenové buňky $x účinky léků $x metabolismus $7 D059630
- 650 _2
- $a rosiglitazon $x farmakologie $7 D000077154
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a hypoglykemika $x farmakologie $7 D007004
- 650 _2
- $a pioglitazon $x farmakologie $7 D000077205
- 650 _2
- $a buněčná diferenciace $x účinky léků $7 D002454
- 650 _2
- $a metabolomika $7 D055432
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rahm, Michal $u Chemistry of Bioconjugates, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague, Czechia
- 700 1_
- $a Benova, Andrea $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 700 1_
- $a Domanska, Veronika $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 700 1_
- $a Reyes-Gutierez, Paul $u Chemistry of Bioconjugates, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague, Czechia
- 700 1_
- $a Dzubanova, Martina $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia; Faculty of Science, Charles University, Albertov 6, 128 00 Prague, Czech Republic
- 700 1_
- $a Trubacova, Radka $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 700 1_
- $a Vondrackova, Michaela $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 700 1_
- $a Cajka, Tomas $u Laboratory of Translational Metabolism, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 700 1_
- $a Tencerova, Michaela $u Laboratory of Molecular Physiology of Bone, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia
- 700 1_
- $a Vrabel, Milan $u Chemistry of Bioconjugates, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague, Czechia
- 700 1_
- $a Kuda, Ondrej $u Laboratory of Metabolism of Bioactive Lipids, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14200 Prague, Czechia. Electronic address: ondrej.kuda@fgu.cas.cz
- 773 0_
- $w MED00010225 $t Metabolism, clinical and experimental $x 1532-8600 $g Roč. 166 (20250211), s. 156157
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39947516 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135049 $b ABA008
- 999 __
- $a ok $b bmc $g 2310961 $s 1246377
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 166 $c - $d 156157 $e 20250211 $i 1532-8600 $m Metabolism, clinical and experimental $n Metabolism $x MED00010225
- LZP __
- $a Pubmed-20250415